Rangel Carlos, Shu Richard G, Lazar Lawrence D, Vittinghoff Eric, Hsue Priscilla Y, Marcus Gregory M
Harvard Medical School, Boston, Massachusetts, USA.
Arch Intern Med. 2010 May 24;170(10):874-9. doi: 10.1001/archinternmed.2010.115.
Although beta-blockers prevent adverse events after myocardial infarction, they are contraindicated when chest pain is associated with recent cocaine use. Recommendations against this use of beta-blockers are based on animal studies, small human experiments, and anecdote. We sought to test the hypothesis that beta-blockers are safe in this setting.
We performed a retrospective cohort study of consecutive patients admitted to the San Francisco General Hospital, San Francisco, California, with chest pain and urine toxicologic test results positive for cocaine, from January 2001 to December 2006. Mortality data were collected from the National Death Index.
Of 331 patients with chest pain in the setting of recent cocaine use, 151 (46%) received a beta-blocker in the emergency department. There were no meaningful differences in electrocardiographic changes, troponin levels, length of stay, use of vasopressor agents, intubation, ventricular tachycardia or ventricular fibrillation, or death between those who did and did not receive a beta-blocker. After adjusting for potential confounders, systolic blood pressure significantly decreased a mean 8.6 mm Hg (95% confidence interval, 14.7-2.5 mm Hg) in those receiving a beta-blocker in the emergency department compared with those who received their first beta-blocker in the hospital ward (P = .006). Over a median follow-up of 972 days (interquartile range, 555-1490 days), after adjusting for potential confounders, patients discharged on a beta-blocker regimen exhibited a significant reduction in cardiovascular death (hazard ratio, 0.29; 95% confidence interval, 0.09-0.98) (P = .047).
beta-Blockers do not appear to be associated with adverse events in patients with chest pain with recent cocaine use.
尽管β受体阻滞剂可预防心肌梗死后的不良事件,但当胸痛与近期使用可卡因相关时,β受体阻滞剂为禁忌用药。反对使用β受体阻滞剂的建议基于动物研究、小规模人体实验及轶事。我们试图验证β受体阻滞剂在此种情况下是安全的这一假设。
我们对2001年1月至2006年12月期间因胸痛入住加利福尼亚州旧金山总医院且尿液毒理学检测可卡因呈阳性的连续患者进行了一项回顾性队列研究。从国家死亡指数收集死亡率数据。
在331例近期使用可卡因且伴有胸痛的患者中,151例(46%)在急诊科接受了β受体阻滞剂治疗。接受和未接受β受体阻滞剂治疗的患者在心电图变化、肌钙蛋白水平、住院时间、血管升压药使用、插管、室性心动过速或心室颤动以及死亡方面均无显著差异。在调整潜在混杂因素后,与在医院病房首次接受β受体阻滞剂治疗的患者相比,在急诊科接受β受体阻滞剂治疗的患者收缩压平均显著降低8.6 mmHg(95%置信区间为14.7 - 2.5 mmHg)(P = 0.006)。在中位随访972天(四分位间距为555 - 1490天)期间,调整潜在混杂因素后,出院时接受β受体阻滞剂治疗方案的患者心血管死亡显著降低(风险比为0.29;95%置信区间为0.09 - 0.98)(P = 0.047)。
对于近期使用可卡因且伴有胸痛的患者,β受体阻滞剂似乎与不良事件无关。